August 2025 updates to the Universal Influenza Vaccine Technology Landscape include the following: 

• Osivax announced $19.5 million in funding from the US Biomedical Advanced Research and Development Authority (BARDA) to advance development of OVX835, including preparation for a large-scale efficacy trial and process development for manufacturing scale-up (press release 8-26-2025)
• NIAID began recruitment for a new phase 1 trial to examine the safety, tolerability, and immunogenicity of a quadrivalent influenza HA stem nanoparticle vaccine, SteMos1, with and without ALFQ adjuvant (NCT07111078)
• Preclinical study at Iowa State University of an intranasal polymer-based nanoparticle vaccine with H3 antigen from an equine H3N8 virus and nucleoprotein antigen from an H3N2 virus, aimed at eliciting broadly protective humoral and cellular immune responses, reported in Siddoway 2025
• “Beads-on-a-string” (BOAS) multivalent immunogens, tandemly linked HA subtypes conjugated to ferritin nanoparticles, developed at Harvard University, reported in Lamson 2025 (preprint)
• Dental floss-based mucosal vaccine containing conserved M2e antigens on a nanoparticle platform reported in Ingrole 2025

For more recent updates and additional information, see the Landscape.